Although HER2 amplification occurs in roughly 1% of NSCLC cases, its incidence increases post-osimertinib: data from trials like AURA and FLAURA confirm HER2 amplification rates of about 5% in second-line and 2% in first-line resistance, often in the absence of T790M mutations [32,40]. Here, ERBB2 is linked to non-small cell lung carcinoma.